Discovery and utilization of haplotypes for pharmacogenetic studies of psychotropic drug response

Psychiatric Genetics

Volumn 12, Issue 2, 2002, Pages 89-96

  Athanasiou, Maria C ^a   Malhotra, Anil K ^a   Xu, Chuanbo ^a   Stephens, J Claiborne ^a  

^a Clinical Data Inc   (United States)

Author keywords

Drug response; Haplotype; Pharmacogenetics; Phenotype; Single nucleotide polymorphism

Indexed keywords

PSYCHOTROPIC AGENT;

DRUG INDUCED DISEASE; DRUG RESPONSE; GENE SEQUENCE; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; MENTAL DISEASE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ARTICLE; DRUG INDUSTRY; GENETIC MARKER; GENETICS; METHODOLOGY;

DRUG INDUSTRY; GENETIC MARKERS; HAPLOTYPES; HUMAN; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHOTROPIC DRUGS; HUMANS;

EID: 0035986208     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041444-200206000-00006     Document Type: Review

References (24)

1. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
2. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia
3. Plasma catecholamine metabolites and early response to haloperidol
4. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia
5. Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase
6. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness
7. Schizophrenia: Clinical features
8. Archaic African and Asian lineages in the genetic ancestry of modern humans
9. Serotonin function and treatment response to clozapine in schizophrenic patients
10. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
11. Biologic predictors of clozapine response in schizophrenia
12. Benefits and pitfalls encountered in psychiatric genetic association studies
13. Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine
14. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics
15. Pharmacogenetic assessment of antipsychotic-induced movement disorders: Contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes
16. Nucleotide sequence diversity in non-coding regions of ALDH2 as revealed by restriction enzyme and SSCP analysis
17. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients
18. Automating the identification of DNA variations using quality-based fluorescence re-sequencing: Analysis of the human mitochondrial genome
19. Haplotype variation and linkage disequilibrium in 313 human genes
20. Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: Preliminary findings
21. Locating regions of differential variability in DNA and protein sequences
22. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome
23. Patterns of ancestral human diversity: An analysis of Alu-insertion and restriction-site polymorphisms
24. Is the most frequent allele the oldest?